K12, CA-0906525/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2013	2
2014	4
2015	7
2016	1
2024	0

1

Therapeutic Advances and Treatment Options in Metastatic Melanoma.

Johnson DB, Sosman JA. Johnson DB, et al. JAMA Oncol. 2015 Jun;1(3):380-6. doi: 10.1001/jamaoncol.2015.0565. JAMA Oncol. 2015. PMID: 26181188 Review.

2

Targeting angiogenesis in advanced non-small cell lung cancer.

Lammers PE, Horn L. Lammers PE, et al. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1235-47. doi: 10.6004/jnccn.2013.0146. J Natl Compr Canc Netw. 2013. PMID: 24142825 Free PMC article. Review.

3

Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.

Johnson DB, Smalley KS, Sosman JA. Johnson DB, et al. Clin Cancer Res. 2014 Aug 15;20(16):4186-92. doi: 10.1158/1078-0432.CCR-13-3270. Epub 2014 Jun 3. Clin Cancer Res. 2014. PMID: 24895460 Free PMC article. Review.

4

Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Lovly CM, Shaw AT. Lovly CM, et al. Clin Cancer Res. 2014 May 1;20(9):2249-56. doi: 10.1158/1078-0432.CCR-13-1610. Clin Cancer Res. 2014. PMID: 24789032 Free PMC article. Review.

5

Melanoma and a Headache. Diagnosis: Hypophysitis.

Johnson DB, Mudigonda TV, Sosman JA. Johnson DB, et al. JAMA Oncol. 2015 Nov;1(8):1167-8. doi: 10.1001/jamaoncol.2015.2537. JAMA Oncol. 2015. PMID: 26225893 No abstract available.

6

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. Mudigonda TV, et al. Pigment Cell Melanoma Res. 2016 Jan;29(1):101-3. doi: 10.1111/pcmr.12394. Epub 2015 Aug 20. Pigment Cell Melanoma Res. 2016. PMID: 26176864 Clinical Trial. No abstract available.

7

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. Johnson DB, et al. Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092. Cancer Immunol Res. 2013. PMID: 24490176 Free PMC article.

8

Treatment of NRAS-mutant melanoma.

Johnson DB, Puzanov I. Johnson DB, et al. Curr Treat Options Oncol. 2015 Apr;16(4):15. doi: 10.1007/s11864-015-0330-z. Curr Treat Options Oncol. 2015. PMID: 25796376 Free PMC article. Review.

9

Immune checkpoint inhibitors in NSCLC.

Johnson DB, Rioth MJ, Horn L. Johnson DB, et al. Curr Treat Options Oncol. 2014 Dec;15(4):658-69. doi: 10.1007/s11864-014-0305-5. Curr Treat Options Oncol. 2014. PMID: 25096781 Free PMC article. Review.

10

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Johnson DB, Puzanov I, Kelley MC. Johnson DB, et al. Immunotherapy. 2015;7(6):611-9. doi: 10.2217/imt.15.35. Epub 2015 Jun 22. Immunotherapy. 2015. PMID: 26098919 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year